Academic Journal
Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea
| Title: | Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea |
|---|---|
| Authors: | Ji Yeon Lee, Seon Hee Bu, EunHyang Song, Seongcheol Cho, Sungbong Yu, Jungok Kim, Sungmin Kym, Kwang Won Seo, Ki Tae Kwon, Jin Yong Kim, Sunghyun Kim, Keumyoung Ahn, Nahyun Jung, Yeonmi Lee, Yoobin Jung, Chankyoung Hwang, Sang Won Park |
| Source: | Infectious Diseases and Therapy, Vol 12, Iss 10, Pp 2417-2435 (2023) |
| Publisher Information: | Adis, Springer Healthcare, 2023. |
| Publication Year: | 2023 |
| Collection: | LCC:Infectious and parasitic diseases |
| Subject Terms: | COVID-19, CT-P59, Effectiveness, Monoclonal antibody, Neutralising antibody, Post-marketing surveillance, Infectious and parasitic diseases, RC109-216 |
| More Details: | Abstract Introduction Regdanvimab, a neutralising monoclonal antibody (mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), received approval for the treatment of coronavirus disease 2019 (COVID-19) in South Korea in 2021. The Ministry of Food and Drug Safety in South Korea mandate that new medications be re-examined for safety and effectiveness post-approval in at least 3000 individuals. This post-marketing surveillance (PMS) study was used to evaluate the safety and effectiveness of regdanvimab in real-world clinical care. Methods This prospective, multicentre, phase 4 PMS study was conducted between February 2021 and March 2022 in South Korea. Eligible patients were aged ≥ 18 years with confirmed mild COVID-19 at high risk of disease progression or moderate COVID-19. Patients were hospitalised and treated with regdanvimab (40 mg/kg, day 1) and then monitored until discharge, with a follow-up call on day 28. Adverse events (AEs) were documented, and the COVID-19 disease progression rate was used to measure effectiveness. Results Of the 3123 patients with COVID-19 infection identified, 3036 were eligible for inclusion. Approximately 80% and 5% of the eligible patients were diagnosed with COVID-19 during the delta- and omicron-dominant periods, respectively. Median (range) age was 57 (18–95) years, and 50.6% of patients were male. COVID-19 severity was assessed before treatment, and high-risk mild and moderate COVID-19 was diagnosed in 1030 (33.9%) and 2006 (66.1%) patients, respectively. AEs and adverse drug reactions (ADRs) were experienced by 684 (22.5%) and 363 (12.0%) patients, respectively. The most common ADR was increased liver function test (n = 62, 2.0%). Nine (0.3%) patients discontinued regdanvimab due to ADRs. Overall, 378 (12.5%) patients experienced disease progression after regdanvimab infusion, with extended hospitalisation/re-admission (n = 300, 9.9%) as the most common reason. Supplemental oxygen was required by 282 (9.3%) patients. Ten (0.3%) patients required intensive care monitoring and 3 (0.1%) died due to COVID-19. Conclusion This large-scale PMS study demonstrated that regdanvimab was effective against COVID-19 progression and had an acceptable safety profile when used in real-world clinical practice. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2193-8229 2193-6382 |
| Relation: | https://doaj.org/toc/2193-8229; https://doaj.org/toc/2193-6382 |
| DOI: | 10.1007/s40121-023-00859-1 |
| Access URL: | https://doaj.org/article/2cfbe7051ee749f38846304a4ed3b6f1 |
| Accession Number: | edsdoj.2cfbe7051ee749f38846304a4ed3b6f1 |
| Database: | Directory of Open Access Journals |
| Full text is not displayed to guests. | Login for full access. |
| ISSN: | 21938229 21936382 |
|---|---|
| DOI: | 10.1007/s40121-023-00859-1 |
| Published in: | Infectious Diseases and Therapy |
| Language: | English |